Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women☆

Autor: Joaquín Luna, Eugenio Suarez, Gonzalo Perez, Miguel Cashat, Santos Uscanga, Manuel Plata, Christine Shields, Edson D. Moreira, Francisco Revollo, Edison Natal Fedrizzi, Jaime Alberto Restrepo, Rosires Pereira de Andrade, Alain Luxembourg, Claudia Nossa Dominguez, Michael Ritter, Julio C. Reina, Ana Maria Guevara, Robinson Cabello, Arnaldo Silva, Alejandro Victoria, Erin Moeller, Misoo C. Ellison, Eduardo Lazcano-Ponce, Ángela María Ruiz-Sternberg

Publikováno v: Papillomavirus Research
International Agency for Research on Cancer, GLOBOCAN 2012: estimated cancer incidence (2012) Mortal. Preval. Worldw., http://globocan.iarc.fr/Pages/fact_sheets_population.aspx, (accessed 12 June 2017)
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario
Papillomavirus Research, Vol 5, Iss, Pp 63-74 (2018)

Background: A 9-valent human papillomavirus (HPV6/11/16/18/31/33/45/52/58; 9vHPV) vaccine was developed to expand coverage of the previously developed quadrivalent (HPV6/11/16/18; qHPV) vaccine. Methods: Efficacy, immunogenicity, and safety outcomes

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::781a104dd5a6e213aea23cff2c31587f
http://europepmc.org/articles/PMC5887018

Effectiveness and safety of cabazitaxel chemotherapy for metastatic castration-resistant prostatic carcinoma on Turkish patients (The Anatolian Society of Medical Oncology)

Autor: Suner, A., Aydin, D., Bekir Hacioglu, Dogu, G. G., Imamoglu, G. I., Menekse, S., Pilanci, K. N., Yazici, O. K., Koca, D., Karaagac, M., Akyol, M., Akman, T., Ergen, S., Avci, N., Kacan, T., Bozkurt, O., Kefeli, U., Urakci, Z., Araz, M., Arpaci, E., Harputlu, H., Sevinc, A.

Publikováno v: Web of Science

WOS: 000376904300006
PubMed ID: 27097941
OBJECTIVE: Prostate cancer is among the most common cancers in males. Prostate cancer is androgen dependent in the beginning, but as time progresses, it becomes refractory to androgen deprivation tre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::087d9b64aee278174bbb87cd3212c72d
https://hdl.handle.net/20.500.12418/7398

Treating systemic effects of COPD

Autor: Mario Cazzola, Clive P. Page, Paola Rogliani, Maria Gabriella Matera

Publikováno v: Trends in Pharmacological Sciences. 28:544-550

The emerging recognition that chronic obstructive pulmonary disease (COPD) is a complex disorder, characterized not only by local pulmonary inflammation, but also by systemic inflammation that might have an adverse impact on various extrapulmonary or

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c94a862bcc65f8429411a120b5e3968
https://doi.org/10.1016/j.tips.2007.09.006

Azacitidine frontline therapy for unfit acute myeloid leukemia patients: Clinical use and outcome prediction

Autor: Ramos F., Maurillo L., Itzykson R., Bargay J., Stauder R., Venditti A., Seegers V., Gaidano G., Gardin C., Musto P., Greil R., Sánchez-Guijo F., Fenaux P., Thépot S., Récher C., Raffoux E., Quesnel B., Delaunay J., Cluzeau T., Koka A.M., Stamatoullas A., Chaury M.-P., Gyan E., Cheze S., Banos A., Morel P., Plantier I., Taksin A.-L., Shanti A., Sanhes L., De Botton S., Marolleau J.P., Pautas C., Wattel E., Isnard F., Guerci A., Vey N., Dreyfus F., Ifrah N., Ades L., Martínez-Robles V., Debén G., Garrido A., Casaño J., Salamero O., Bergua J.M., Colado E., García R., Pedro C., Redondo S., Tormo M., Bonanad S., Díez-Campelo M., Pérez-Encinas M., de la Fuente A., Xicoy B., Falantes J.F., Font P., González-López T.J., Martín-Núñez G., Montesinos P., Pleyer L., Burgstaller S., Schreder M., Tinchon C., Pfeilstoecker M., Steinkirchner S., Melchardt T., Mitrovic M., Girschikofsky M., Lang A., Krippl P., Sliwa T., Egle A., Linkesch W., Voskova D., Angermann H., Spagnoli A., Lunghi M., Pietrantuono G., Villani O.

Publikováno v: LEUKEMIA RESEARCH
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
r-FISABIO. Repositorio Institucional de Producción Científica
instname

Hypomethylating agents are able to prolong the overall survival of some patients diagnosed with acute myeloid leukemia. The aim of this study was to evaluate the clinical use of azacitidine as front-line therapy in unfit acute myeloid leukemia (AML)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::590e2de10e9ad075961a7d9d5e48e32d
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84924076153&doi=10.1016/j.leukres.2014.12.013&partnerID=40&md5=95d172f52911e7c83d24334fae23e084

Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial

Autor: Fountzilas, George, Dafni, U., Papadimitriou, C., Timotheadou, E., Gogas, H., Eleftheraki, A. G., Xanthakis, I., Christodoulou, C., Koutras, A. K., Papandreou, C. N., Papakostas, P., Miliaras, S., Markopoulos, C., Dimitrakakis, C., Korantzopoulos, Panagiotis, Karanikiotis, C., Bafaloukos, Dimitrios, Kosmidis, Paraskevas A., Samantas, E., Varthalitis, I., Pavlidis, Nicholas, Pectasides, Dimitrios, Dimopoulos, M. A.

Publikováno v: BMC Cancer

Background: Dose-dense sequential chemotherapy including anthracyclines and taxanes has been established in the adjuvant setting of high-risk operable breast cancer. However, the preferable taxane and optimal schedule of administration in a dose-dens

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86f05a4fb1c5cce316e6477713a4950e
https://pubmed.ncbi.nlm.nih.gov/25026897